333 related articles for article (PubMed ID: 25268716)
41. Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.
Casini A; Gabbiani C; Michelucci E; Pieraccini G; Moneti G; Dyson PJ; Messori L
J Biol Inorg Chem; 2009 Jun; 14(5):761-70. PubMed ID: 19288144
[TBL] [Abstract][Full Text] [Related]
42. The contrasting catalytic efficiency and cancer cell antiproliferative activity of stereoselective organoruthenium transfer hydrogenation catalysts.
Fu Y; Sanchez-Cano C; Soni R; Romero-Canelon I; Hearn JM; Liu Z; Wills M; Sadler PJ
Dalton Trans; 2016 May; 45(20):8367-78. PubMed ID: 27109147
[TBL] [Abstract][Full Text] [Related]
43. Metal-based anticancer chemotherapeutic agents.
Muhammad N; Guo Z
Curr Opin Chem Biol; 2014 Apr; 19():144-53. PubMed ID: 24608084
[TBL] [Abstract][Full Text] [Related]
44. Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Kenny RG; Marmion CJ
Chem Rev; 2019 Jan; 119(2):1058-1137. PubMed ID: 30640441
[TBL] [Abstract][Full Text] [Related]
45. Beyond platinums: gold complexes as anticancer agents.
Nardon C; Boscutti G; Fregona D
Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
[TBL] [Abstract][Full Text] [Related]
46. Ruthenium(II/III)-based compounds with encouraging antiproliferative activity against non-small-cell lung cancer.
Nagy EM; Pettenuzzo A; Boscutti G; Marchiò L; Dalla Via L; Fregona D
Chemistry; 2012 Nov; 18(45):14464-72. PubMed ID: 23012112
[TBL] [Abstract][Full Text] [Related]
47. Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes.
Gałczyńska K; Drulis-Kawa Z; Arabski M
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751963
[TBL] [Abstract][Full Text] [Related]
48. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
49. Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions.
Riddell IA
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394020
[TBL] [Abstract][Full Text] [Related]
50. Phosphorescence monitoring of hypoxic microenvironment in solid-tumors to evaluate chemotherapeutic effects using the hypoxia-sensitive iridium (III) coordination compound.
Zeng Y; Liu Y; Shang J; Ma J; Wang R; Deng L; Guo Y; Zhong F; Bai M; Zhang S; Wu D
PLoS One; 2015; 10(3):e0121293. PubMed ID: 25786221
[TBL] [Abstract][Full Text] [Related]
51. Computational Studies of Au(I) and Au(III) Anticancer MetalLodrugs: A Survey.
Tolbatov I; Marrone A; Coletti C; Re N
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946684
[TBL] [Abstract][Full Text] [Related]
52. Metal complexes with aromatic N-containing ligands as potential agents in cancer treatment.
Zhao G; Lin H
Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):137-47. PubMed ID: 15777221
[TBL] [Abstract][Full Text] [Related]
53. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.
Zhang X; Liu D; Lv F; Yu B; Shen Y; Cong H
Colloids Surf B Biointerfaces; 2019 Oct; 182():110373. PubMed ID: 31376689
[TBL] [Abstract][Full Text] [Related]
54. Metal-N-heterocyclic carbene complexes as anti-tumor agents.
Hu C; Li X; Wang W; Zhang R; Deng L
Curr Med Chem; 2014 Apr; 21(10):1220-30. PubMed ID: 24350852
[TBL] [Abstract][Full Text] [Related]
55. Copper Complexes in Cancer Therapy.
Denoyer D; Clatworthy SAS; Cater MA
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394035
[TBL] [Abstract][Full Text] [Related]
56. Novel cyclometalated Ru(II) complexes containing isoquinoline ligands: Synthesis, characterization, cellular uptake and in vitro cytotoxicity.
Chen J; Wang J; Deng Y; Li B; Li C; Lin Y; Yang D; Zhang H; Chen L; Wang T
Eur J Med Chem; 2020 Oct; 203():112562. PubMed ID: 32698112
[TBL] [Abstract][Full Text] [Related]
57. Transport of the Ruthenium Complex [Ru(GA)(dppe)
Naves MA; Graminha AE; Vegas LC; Luna-Dulcey L; Honorato J; Menezes ACS; Batista AA; Cominetti MR
Mol Pharm; 2019 Mar; 16(3):1167-1183. PubMed ID: 30633527
[TBL] [Abstract][Full Text] [Related]
58. Mechanistic and cytotoxicity studies of group IV β-diketonate complexes.
Lord RM; Mannion JJ; Hebden AJ; Nako AE; Crossley BD; McMullon MW; Janeway FD; Phillips RM; McGowan PC
ChemMedChem; 2014 Jun; 9(6):1136-9. PubMed ID: 24782045
[TBL] [Abstract][Full Text] [Related]
59. Novel NHC-coordinated ruthenium(II) arene complexes achieve synergistic efficacy as safe and effective anticancer therapeutics.
Chen C; Xu C; Li T; Lu S; Luo F; Wang H
Eur J Med Chem; 2020 Oct; 203():112605. PubMed ID: 32688202
[TBL] [Abstract][Full Text] [Related]
60. [RuII(η⁵-C₅H₅)(bipy)(PPh₃)]⁺, a promising large spectrum antitumor agent: cytotoxic activity and interaction with human serum albumin.
Tomaz AI; Jakusch T; Morais TS; Marques F; de Almeida RF; Mendes F; Enyedy EA; Santos I; Pessoa JC; Kiss T; Garcia MH
J Inorg Biochem; 2012 Dec; 117():261-9. PubMed ID: 22877927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
